What Is Medetomidine and Why Is It Now in Maine’s Drug Supply?

A new and more dangerous adulterant is showing up in illicit opioids across the Northeast, and Maine is not immune. It’s called medetomidine, and if you or someone you love uses substances, this is information that could save a life.

At Portland Treatment in Biddeford, Maine, we stay closely connected to what’s happening in our communities, from Portland’s Old Port to the mill towns and rural stretches of York and Cumberland counties. What we’re seeing in the drug supply right now concerns us deeply, and we want people in southern Maine to have the facts.

What Is Medetomidine?

Medetomidine is a veterinary sedative — a drug designed to anesthetize large animals like dogs and deer during medical procedures. It is not approved for human use. Like xylazine (which many Mainers already know as “tranq”), medetomidine is now being used to bulk up illicit fentanyl, often without the person using the drug having any idea it’s there.

But medetomidine is not simply the next xylazine. It is significantly more dangerous.

According to the Maine Drug Monitoring Initiative, medetomidine’s potency is estimated to be 200 to 300 times greater than that of xylazine — a drug that was already alarming enough on its own. It causes longer and heavier sedation, more severe withdrawal symptoms, and can lead to life-threatening drops in heart rate and blood pressure.

On the street, it sometimes goes by “rhino tranq” — but most people who encounter it don’t know it’s there at all.

How Widespread Is This Problem?

The spread of medetomidine has been rapid. Nationally, data from a drug checking program tracking over 11,000 samples found that medetomidine appeared in fewer than 1% of samples before mid-2024 — and then surged sharply. In New York state, it was detected in 37% of opioid samples by October 2025, up from just 4% the prior year.

Maine’s own monitoring systems have confirmed its presence in the Northeast’s drug supply, with the Maine Drug Monitoring Initiative flagging medetomidine as an increasingly dangerous development in the illicit opioid market. Because Maine sits in the heart of the Northeast corridor — and because fentanyl from the same supply chains reaches communities from Bangor to Biddeford — what’s being detected in Massachusetts and New York is also making its way here.

Research shows that roughly 91% of drug samples containing medetomidine also contain fentanyl, and more than half also contain another sedative such as xylazine. That combination — fentanyl, xylazine, and medetomidine stacked together — creates an overdose profile that is unlike anything clinicians or first responders have encountered before.

Why Medetomidine Makes Overdoses More Dangerous

Here is the part that matters most for anyone in Maine who uses substances, or anyone who loves someone who does.

Naloxone alone may not be enough.

Naloxone (Narcan) reverses opioid overdose by blocking opioid receptors. But medetomidine is not an opioid. It works through a completely different pathway — the alpha-2 adrenergic receptor system — which naloxone cannot touch. So even if you administer naloxone and someone’s breathing improves, they may remain heavily sedated because of the medetomidine still in their system.

This does not mean you skip the naloxone. Administering naloxone is still the right first step and can restore breathing. But it does mean that seeming to partially respond to naloxone is not the same as being safe. The person may still be in serious danger, and emergency medical care is essential.

Other warning signs of medetomidine involvement in an overdose include:

• Unusual depth of sedation that doesn’t respond normally to naloxone
• Dangerously slow heart rate
• Severely low blood pressure
• Vomiting combined with unresponsiveness
• Prolonged sedation lasting far longer than a typical fentanyl overdose

If you see any of these signs, call 911 immediately. Maine’s Good Samaritan law protects you from drug charges when you call for help during an overdose.

The Withdrawal Problem No One Is Talking About

There is another layer to the medetomidine crisis that isn’t getting enough attention: withdrawal.

People who have been regularly exposed to medetomidine — even unknowingly — can develop physical dependence on it. And medetomidine withdrawal goes far beyond what’s seen with opioids alone. Case reports out of Pittsburgh documented severe withdrawal syndromes requiring ICU-level care, including extreme spikes in blood pressure, agitation, and cardiovascular instability.

This matters enormously for treatment in Maine. Someone entering detox who has been using fentanyl that contains medetomidine may experience a much more complicated and medically serious withdrawal than providers or the person themselves would anticipate. Standard opioid withdrawal protocols may not be sufficient.

This is one of the most important reasons to seek professionally supervised care — not to go it alone.

What This Means If You’re Seeking Help in Southern Maine

If you or someone you care about is using illicit opioids in Maine right now, the risk level has escalated. The drug supply is more unpredictable than it has ever been. Substances that look, smell, and feel the same can contain wildly different combinations of fentanyl, xylazine, medetomidine, and other adulterants — with no way to know from the outside.

At Portland Treatment, located in Biddeford and serving all of southern Maine, we understand this landscape. Our clinical team monitors emerging threats in the drug supply because the people who walk through our doors deserve care that reflects what they’re actually up against — not what the crisis looked like five years ago.

We offer:

• PHP (Partial Hospitalization Program) — structured, intensive daily treatment that allows you to return home each evening
• IOP (Intensive Outpatient Program) — flexible scheduling that fits around your work, family, or other responsibilities
• Medication management — including evidence-based medications to support opioid use disorder treatment and reduce cravings
• Individual, group, and family therapy — because addiction doesn’t just affect one person
• Trauma-informed care — because in Maine, as in most of New England, the opioid crisis has been intertwined with trauma for a long time

We also accept most major insurance plans, including MaineCare, Anthem, BCBS, Cigna, Harvard Pilgrim, Martin’s Point, Tufts, and more. Cost should not be the reason someone waits.

You Don’t Have to Understand the Whole Crisis to Take One Step

Medetomidine is a complicated drug with a complicated name. But what it means in plain terms is this: the drugs on Maine’s streets are more dangerous than ever, in ways that are harder to see and harder to survive without help.

You don’t have to know all the pharmacology. You just have to know that the window for making it out safely keeps getting smaller, and that treatment works.

If you’re ready to talk, we’re ready to listen.

Call Portland Treatment 24/7: 855-449-7674

Frequently Asked Questions

Sources

1. Maine Drug Monitoring Initiative. (June 2025). Maine Drug Monitoring Initiative Statewide Report. Maine Information and Analysis Center. https://mainedrugdata.org
2. New York State Department of Health. (December 19, 2025). Updated Public Health Alert: Medetomidine in the Drug Supply. https://www.health.ny.gov
3. Sibley, A., et al. (2025). Emergence of medetomidine in the unregulated drug supply and its association with hallucinogenic effects. Drug and Alcohol Review. https://doi.org/10.1111/dar.70024
4. Lynch, M.J., Pizon, A.F., & Yealy, D.M. (2026). Emergence of medetomidine in the illicit drug supply: Implications for emergency care and withdrawal management. Annals of Emergency Medicine. https://doi.org/10.1016/j.annemergmed.2025.12.004
5. Palamar, J.J., et al. (2024). Medetomidine infiltrates the US illicit opioid market. JAMA, 332(17), 1425–1426. https://doi.org/10.1001/jama.2024.15992
6. Allegheny County Health Department. (August 2025). Medetomidine Overdose Surveillance Brief. https://www.med.unc.edu/fammed/nctac
7. Maine Drug Data Hub. (2025). Maine Opioid Response 2023–2025 Strategic Action Plan. https://mainedrugdata.org